Becton, Dickinson and Company
NYSE:BDXMedical - Instruments & Supplies
+$2.36 today
- Market cap
- $58.86B
- Beta
- 0.28
- P/E (TTM)
- 35.5
- EPS (TTM)
- $4.06
- Dividend yield
- 2.60%
Volume 1.32M
Average 2.76M
BDX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Becton, Dickinson and CompanyNYSE: BDX
Operating Expenses · Q4 FY2026 · quarter ended Sep 2026
Operating expenses declines year over year
Q4 FY2026 operating expenses of $1.66B fell 21.0% year over year, behind the -3.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Operating expenses amounted to 35.8% of revenue in FY2026, up 2.1 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -21.0% toward the trailing-twelve-month pace of -3.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2026
- 6.96B USD
- Year-over-year change
- -5.3%
- 4-year CAGR
- +2.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 6.96B | -5.3% |
| FY2025 | 2025-09-30 | 7.35B | +9.2% |
| FY2024 | 2024-09-30 | 6.73B | +11.0% |
| FY2023 | 2023-09-30 | 6.06B | -2.2% |
| FY2022 | 2022-09-30 | 6.2B | — |
Operating Expenses vs competitors
How BDX compares with its peers on the latest reported figures
- BDX's LTM Sep 2026 operating expenses of $7.12B is the 3rd highest of the 11 companies compared; the peer median is $1.01B.
- Its year-over-year change of -3.0% is the 6th highest of 11, against a peer median of +1.8%.
- Operating expenses amounts to 35.2% of revenue for BDX, versus a peer median of 34.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $20.2B | +27.0% | +5.9% | 41.9% | |
| LTM Jul 2026 | $18.25B | +17.2% | +4.6% | 48.6% | |
| LTM Sep 2026 | $7.12B | -3.0% | +4.7% | 35.2% | |
| LTM Jun 2026 | $3.72B | -3.9% | -16.8% | 32.5% | |
| LTM Jun 2026 | $2.47B | -35.0% | -8.9% | 29.7% | |
| LTM Jun 2026 | $1.31B | -4.4% | -5.7% | 50.4% | |
| LTM Jun 2026 | $702.41M | -10.0% | -1.3% | 32.5% | |
| LTM Sep 2026 | $578.71M | +7.5% | +8.6% | 35.9% | |
| LTM Jun 2026 | $536M | +27.5% | +9.0% | 16.1% | |
| LTM Mar 2026 | $341.3M | -22.9% | -4.1% | 32.7% | |
| LTM Mar 2026 | $74.63M | +94.5% | +12.0% | 74.8% | |
| Peer median (excluding BDX) | $1.01B | +1.8% | +1.6% | 34.3% | |
Competitors are the stored peer set for BDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 18.87B | 19.37B | 20.18B | 21.84B | 19.46B |
| Cost of Revenue | 10.39B | 11.2B | 11.05B | 11.92B | 10.24B |
| Gross Profit | 8.48B | 8.17B | 9.13B | 9.92B | 9.21B |
| Gross Margin | 44.9% | 42.2% | 45.2% | 45.4% | 47.4% |
| Research & Development | 1.26B | 1.24B | 1.19B | 1.26B | 988M |
| Selling, General & Admin | 4.71B | 4.72B | 4.86B | 5.28B | 4.97B |
| Operating Expenses | 6.2B | 6.06B | 6.73B | 7.35B | 6.96B |
| Depreciation & Amortization | 2.23B | 2.29B | 2.29B | 2.46B | 2.24B |
| EBITDA | 4.41B | 4.4B | 4.82B | 4.96B | 4.61B |
| EBITDA Margin | 23.4% | 22.7% | 23.9% | 22.7% | 23.7% |
| Operating Income | 2.28B | 2.11B | 2.4B | 2.58B | 2.26B |
| Operating Margin | 12.1% | 10.9% | 11.9% | 11.8% | 11.6% |
| Interest Income | 16M | 49M | 163M | 38M | 27M |
| Interest Expense | 398M | 452M | 528M | 613M | 564M |
| Other Income / Expenses | (499M) | (449M) | (392M) | (696M) | (451M) |
| Income Before Tax | 1.78B | 1.66B | 2.01B | 1.88B | 1.81B |
| Pre-Tax Margin | 9.4% | 8.6% | 9.9% | 8.6% | 9.3% |
| Income Tax Expense | 148M | 132M | 300M | 204M | 388M |
| Net Income | 1.78B | 1.48B | 1.71B | 1.68B | 1.15B |
| Net Margin | 9.4% | 7.7% | 8.4% | 7.7% | 5.9% |
| EPS (Basic) | 5.93 | 4.97 | 5.88 | 5.84 | 4.11 |
| EPS (Diluted) | 5.88 | 4.94 | 5.86 | 5.83 | 4.09 |
| Weighted Avg Shares | 285.01M | 286.28M | 289.76M | 286.61M | 278.49M |
| Weighted Avg Shares (Diluted) | 287.36M | 288.39M | 291.01M | 287.12M | 279.94M |
Becton, Dickinson and Company
NYSE:BDX
Intrinsic Alpha fair value
Locked
Current Price
$216.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.